Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

You may be eligible if

• Adults ≥18 years of age
• Clinical diagnosis of T1D
• GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
• Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
• Willing and able to provide informed consent